Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

2.

Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.

Guo Z, Wang H, Meng F, Li J, Zhang S.

J Transl Med. 2015 Jul 29;13:247. doi: 10.1186/s12967-015-0613-y.

3.

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.

Crespo J, Sun H, Welling TH, Tian Z, Zou W.

Curr Opin Immunol. 2013 Apr;25(2):214-21. doi: 10.1016/j.coi.2012.12.003. Epub 2013 Jan 6. Review.

4.

CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy.

He QF, Xu Y, Li J, Huang ZM, Li XH, Wang X.

Brief Funct Genomics. 2019 Mar 22;18(2):99-106. doi: 10.1093/bfgp/ely006.

PMID:
29554204
5.

Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.

Prezzemolo T, Guggino G, La Manna MP, Di Liberto D, Dieli F, Caccamo N.

Front Immunol. 2014 Apr 22;5:180. doi: 10.3389/fimmu.2014.00180. eCollection 2014. Review.

6.

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+ T-cell proliferation and survival.

Abu Eid R, Friedman KM, Mkrtichyan M, Walens A, King W, Janik J, Khleif SN.

Oncoimmunology. 2015 Feb 3;4(5):e1005448. eCollection 2015 May.

7.

[Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].

Benchetrit F, Gazagne A, Adotevi O, Haicheur N, Godard B, Badoual C, Fridman WH, Tartour E.

Bull Cancer. 2003 Aug-Sep;90(8-9):677-85. Review. French.

8.

Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.

Thounaojam MC, Dudimah DF, Pellom ST Jr, Uzhachenko RV, Carbone DP, Dikov MM, Shanker A.

Oncotarget. 2015 Oct 20;6(32):32439-55. doi: 10.18632/oncotarget.5857.

9.

Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression.

Zhang Y, Ertl HC.

Front Immunol. 2016 Feb 10;7:32. doi: 10.3389/fimmu.2016.00032. eCollection 2016. Review.

10.

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.

Redmond WL, Gough MJ, Weinberg AD.

Eur J Immunol. 2009 Aug;39(8):2184-94. doi: 10.1002/eji.200939348.

11.

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.

Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X.

J Transl Med. 2014 Feb 7;12:36. doi: 10.1186/1479-5876-12-36.

12.

Cytokine-like molecule CCDC134 contributes to CD8⁺ T-cell effector functions in cancer immunotherapy.

Huang J, Xiao L, Gong X, Shao W, Yin Y, Liao Q, Meng Y, Zhang Y, Ma D, Qiu X.

Cancer Res. 2014 Oct 15;74(20):5734-45. doi: 10.1158/0008-5472.CAN-13-3132. Epub 2014 Aug 14.

13.

Neuropilin-1 expression is induced on tolerant self-reactive CD8+ T cells but is dispensable for the tolerant phenotype.

Jackson SR, Berrien-Elliott M, Yuan J, Hsueh EC, Teague RM.

PLoS One. 2014 Oct 24;9(10):e110707. doi: 10.1371/journal.pone.0110707. eCollection 2014.

14.

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.

Cancer Res. 2003 May 15;63(10):2535-45.

15.

Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.

Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, Yang PC, Cheng AL.

Int J Cancer. 2014 Jan 15;134(2):319-31. doi: 10.1002/ijc.28362. Epub 2013 Jul 30.

16.

Monitoring multifunctionality of immune-exhausted CD8 T cells in cancer patients.

Eikawa S, Mizukami S, Udono H.

Methods Mol Biol. 2014;1142:11-7. doi: 10.1007/978-1-4939-0404-4_2.

PMID:
24706270
17.

CD8 T cell exhaustion in human visceral leishmaniasis.

Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, Sundar S, Nylén S.

J Infect Dis. 2014 Jan 15;209(2):290-9. doi: 10.1093/infdis/jit401. Epub 2013 Aug 6.

18.

Human melanoma-specific, noncytolytic CD8+ T cells that can synthesize type I cytokine.

Chakraborty NG, Mukherji B.

Cancer Res. 1998 Apr 1;58(7):1363-6.

19.

Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity.

Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P.

Cancer Res. 2007 Oct 15;67(20):10012-8.

20.

Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression.

Cellerai C, Perreau M, Rozot V, Bellutti Enders F, Pantaleo G, Harari A.

J Virol. 2010 Apr;84(8):3868-78. doi: 10.1128/JVI.02565-09. Epub 2010 Feb 3.

Supplemental Content

Support Center